Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144997 · ClinicalTrials.gov registry record · Phase 4
Lorlatinib Continuation Study
A Phase 4 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Pfizer.
- Active
- Registry status
- Phase 4
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT05144997: Active Phase 4 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by Pfizer.
NCT05144997 is a Phase 4 study of Non-Small Cell Lung Cancer and NSCLC that is active but no longer recruiting, run by Pfizer. The registered enrollment target is 76 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144997, a Phase 4 study of Non-Small Cell Lung Cancer and NSCLC, is active but no longer recruiting, sponsored by Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit further characterization of the safety profile of lorlatinib in participants continuing to receive study intervention
Primary Outcome
Safety collection in this study will permit further characterization of the safety profile of lorlatinib
Conditions Studied
Interventions
- DRUG Lorlatinib
Study Locations (20)
Zhejiang
- The First Affiliated Hospital Zhejiang University School of Medicine - Hangzhou
- Zhejiang Cancer Hospital - Hangzhou
- The Second Affiliated Hospital of Zhejiang University College of Medicine - Hangzhou
Other
- Fudan University Shanghai Cancer Center - Shanghai
- CHU de Rennes - Hôpital Pontchaillou - Rennes
- Institut Gustave Roussy - Villejuif
Beijing Municipality
- Beijing Chest Hospital, Capital Medical University - Beijing
- Beijing Cancer Hospital - Beijing
Jilin
- Jilin Cancer Hospital - Changchun
- The first hospital of jilin university - Changchun
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care - Irvine
Anhui
- The First affiliated Hospital of Anhui Medical University - Hefei
Fujian
- Fujian Cancer Hospital - Fuzhou
Guangdong
- Guangdong Provincial People's Hospital - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-12-28 |
| Est. Completion | 2026-12-28 |
| Phase | Phase 4 |
What the registry record for NCT05144997 still lists
NCT05144997 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Lorlatinib is the first listed.
NCT05144997 names 20 study sites across 14 states, led by Zhejiang, Other, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT05144997 about?
NCT05144997 is a clinical study titled "Lorlatinib Continuation Study". The purpose of this protocol is to provide continued treatment access and safety follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer sponsored lorlatinib parent studies that will be closed. Additional follow-up safety data collection will permit...
What is the current status of trial NCT05144997?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 76 participants. The study started on 2021-12-28. Estimated completion is 2026-12-28.
What conditions does trial NCT05144997 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC.
What interventions are being tested in trial NCT05144997?
The interventions under investigation include: Lorlatinib (DRUG).
Who is sponsoring clinical trial NCT05144997?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05144997 being conducted?
This trial has 20 study locations across California, Anhui, Beijing Municipality, Fujian, Guangdong. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05144997's enrollment target sits among peer trials
76 274th of 454 higher than 177 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Non-small Cell Lung Cancer Registry
COMPLETED · Phase 4
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI